Skip to main content
Premium Trial:

Request an Annual Quote

Bar Harbor BioTechnology, Scienion, Biolog

Premium
Bar Harbor BioTechnology this week launched The Perfect Circle suite of products, which include its GeneSieve bioinformatics, StellArray real-time PCR arrays, and Global Pattern Recognition Bioanalysis applications.
 
Bar Harbor said that when used together, the three products allow scientists to perform gene expression research in a cost-effective manner that eliminates the need to pre-select normalizer genes and increases the sensitivity to significant expression changes in experimental samples.
 

 
Scienion this week launched its sciFlexarrayer S100 high-throughput array and biosensor production instrument. The S100 meets the high-throughput production requirements of common bioarray formats like microtiter plates, slides, wafers and of biosensors, the company said.
 
According to Scienion, the S100 enables users to process individually favored array formats and the system is scalable for production volumes. Compared to the firm’s existing sciFlexarrayer products, the S100 offers substrate carriers that are moved to the dispense heads mounted on its portals via a conveyor. This modular design enables customized solutions and automated production.
 

 
Biolog said last week that its Phenotype MicroArray product line can now enable nearly 1,500 simultaneous phenotypic assays of human and other mammalian cells. Biolog’s PM line previously could only enable 400 potential energy producing pathways of cells.
 
According to Biolog, scientists can now use PM for nitrogen metabolism, ion, hormone, metabolic effector, and cytotoxic anti-cancer drug assays. The assays for nitrogen, ion, and hormone metabolic effects extend the scope of Biolog's core focus by providing assays to assess important aspects of cellular metabolism, while the assays for cytotoxic chemicals expand the assay technology into areas of basic and applied cancer research, toxicology, and chemical biology.
 
PM assays can be used with cell lines as well as with primary cells and do not require any modification or derivation of the cell lines, Biolog said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.